Graham Little-Piccardi-Lassueur syndrome (GLPLS) is a rare lichenoid dermatosis defined by scarring alopecia, loss of pubic and axillary hairs and progressive development of horny follicular papules variously located. Topical or systemic corticosteroids, retinoids or PUVA therapy are the treatments usually proposed and these have partial and temporary benefits. We describe the effectiveness of cyclosporin A in a case of GLPLS at the dosage of 4 mg/kg/day. At the end of treatment, substantial reduction of both perifollicular erythema and follicular hyperkeratotic papules was observed. After 3 months of follow-up, besides the results already obtained, a few areas of hair regrowth in the scarring patches and a more consistent improvement of the follicular papules were detected. We believe that cyclosporin A could be effective mainly in the Initial phases of this rare variant of lichen planopilaris, before the development of severe follicle damage, either by interfering with the acute inflammatory processes or by limiting the progression of the disease. To the best of our knowledge, this is the first report showing a good and persistent therapeutic effect of cyclosporin A in GLPLS.

Bianchi, L., Paro Vidolin, A., Piemonte, P., Carboni, I., Chimenti, S. (2001). Graham Little-Piccardi-Lassueur syndrome: effective treatment with cyclosporin A. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 26(6), 518-520 [10.1046/j.1365-2230.2001.00881.x].

Graham Little-Piccardi-Lassueur syndrome: effective treatment with cyclosporin A

BIANCHI, LUCA;CARBONI, ISABELLA;CHIMENTI, SERGIO
2001-01-01

Abstract

Graham Little-Piccardi-Lassueur syndrome (GLPLS) is a rare lichenoid dermatosis defined by scarring alopecia, loss of pubic and axillary hairs and progressive development of horny follicular papules variously located. Topical or systemic corticosteroids, retinoids or PUVA therapy are the treatments usually proposed and these have partial and temporary benefits. We describe the effectiveness of cyclosporin A in a case of GLPLS at the dosage of 4 mg/kg/day. At the end of treatment, substantial reduction of both perifollicular erythema and follicular hyperkeratotic papules was observed. After 3 months of follow-up, besides the results already obtained, a few areas of hair regrowth in the scarring patches and a more consistent improvement of the follicular papules were detected. We believe that cyclosporin A could be effective mainly in the Initial phases of this rare variant of lichen planopilaris, before the development of severe follicle damage, either by interfering with the acute inflammatory processes or by limiting the progression of the disease. To the best of our knowledge, this is the first report showing a good and persistent therapeutic effect of cyclosporin A in GLPLS.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - Malattie Cutanee e Veneree
English
Con Impact Factor ISI
corticosteroid; cyclosporin A; retinoid; adult; alopecia; article; case report; disease course; drug effect; erythema; female; follow up; graham little piccardi lassueur syndrome; hair loss; human; inflammation; lichen planus; lichenoid eruption; papule; priority journal; PUVA; side effect; Alopecia; Axilla; Back; Cyclosporine; Erythema; Female; Humans; Immunosuppressive Agents; Middle Aged; Scalp; Scleroderma, Systemic; Syndrome
Bianchi, L., Paro Vidolin, A., Piemonte, P., Carboni, I., Chimenti, S. (2001). Graham Little-Piccardi-Lassueur syndrome: effective treatment with cyclosporin A. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 26(6), 518-520 [10.1046/j.1365-2230.2001.00881.x].
Bianchi, L; Paro Vidolin, A; Piemonte, P; Carboni, I; Chimenti, S
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Graham Little-Piccardi-Lassueur syndrome effective treatment with...Clinical and Experimental Dermatology, 2001, 26, 518-520.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 1.05 MB
Formato Adobe PDF
1.05 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/57369
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 26
social impact